KRAS and cancer: K-ras mutations can prevent the enzyme from hydrolyzing GTP, resulting in an up-regulation of downstream signaling activity, which leads to uncontrolled proliferation, resistance to apoptosis, metastasis, and ultimately cancer [9], [10].